Lurasidone for the treatment of bipolar depression: An evidence-based review

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2143-2152

  Franklin, Rachel ^a   Zorowitz, Sam ^a   Corse, Andrew K ^a   Widge, Alik S ^b   Deckersbach, Thilo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Atypical antipsychotic; Bipolar depression; Bipolar disorder; Lurasidone

Indexed keywords

CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; FLUOXETINE PLUS OLANZAPINE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; PLACEBO; PROLACTIN; QUETIAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; TRIACYLGLYCEROL;

AKATHISIA; ARTICLE; BINDING AFFINITY; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERLIPIDEMIA; MONOTHERAPY; NAUSEA; NONHUMAN; PARKINSONISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDE; TREMOR; WEIGHT GAIN;

EID: 84939863225     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S50961     Document Type: Article

References (66)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry. 2007;64(5):543–552.
2. 2007 World Population Data Sheet. Available from: http://www.prb.org/Publications/Datasheets/2007/2007WorldPopulationDataSheet.aspx. Accessed March 23, 2015.
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2013;380(9859):2163–2196.
4. Altamura AC, Serati M, Albano A, Paoli RA, Glick ID, Dell’Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011;261(7):489–508.
5. Kleinman LS, Lowin A, Flood E, Gandhi G, Edgell E, Revicki DA. Costs of bipolar disorder. Pharmacoeconomics. 2003;21(9):601–622.
6. Inflation Calculator: Bureau of Labor Statistics. Available from: http://www.bls.gov/data/inflation_calculator.htm. Accessed March 26, 2015.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM). 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
8. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537.
9. Calabrese JR, Hirschfeld R, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry. 2004;65(11):1499–1504.
10. El-Mallakh RS, Ghaemi SN. Bipolar Depression: A Comprehensive Guide. American Psychiatric Publishing; 2007. Available from: http://books.google.com/books?id=fFKgiZU2KscC
11. Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder. CNS Drugs. 2003;17(7):491–511.
12. Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord. 2009;11(s2):55–76.
13. Beyer JL. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry. 2007;69:31–37.
14. Woo YS, Wang HR, Bahk W-M. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521.
15. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152(11):1635–1640.
16. Fountoulakis KN, Kasper S, Andreassen O, et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2012;262(1):1–48.
17. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012;14(s2):37–50.
18. Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord. 2013;15(1):61–69.
19. Fountoulakis KN, Gazouli M, Kelsoe J, Akiskal H. The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. Eur Neuropsychopharmacol. 2014;25(3):335–342.
20. Lurasidone HCl | C28H37ClN4O2S – PubChem. Available from: http://pubchem.ncbi.nlm.nih.gov/compound/11237860. Accessed March 23, 2015.
21. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat. 2012;8:155.
22. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171–181.
23. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572(2):160–170.
24. Björklund M, Sirviö J, Riekkinen M, Sallinen J, Scheinin M, Riekkinen P. Overexpression of alpha2C-adrenoceptors impairs water maze navigation. Neuroscience. 1999;95(2):481–487.
25. Banasr M, Hery M, Printemps R, Daszuta A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology. 2004;29(3):450–460.
26. Schreiber R, Newman-Tancredi A. Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT 1A receptor activation. Neurobiol Learn Mem. 2014;110:72–80.
27. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29(10):815–825.
28. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E. Effect of the selective 5-HT 7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 2006;51(3):578–586.
29. Guscott M, Bristow LJ, Hadingham K, et al. Genetic knockout and pharmacological blockade studies of the 5-HT 7 receptor suggest therapeutic potential in depression. Neuropharmacology. 2005;48(4):492–502.
30. Huang M, Horiguchi M, Felix AR, Meltzer HY. 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport. 2012;23(7):436–440.
31. Luoni A, Berry A, Calabrese F, et al. Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence. Eur Neuropsychopharmacol. 2014;24(6):986–995.
32. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289–297.
33. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715–1726.
34. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526.
35. Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychoticinduced weight gain–mechanisms and genetics. J Psychopharmacol. 2006;20(4 suppl):15–18.
36. Terry AV, Mahadik SP. Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther. 2007;320(3):961–968.
37. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497–502.
38. Sunovion Pharmaceuticals Inc. Latuda® (lurasidone HCI tablets) [prescribing information]. 2013.
39. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
40. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177.
41. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27.
42. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008;117(6):412–419.
43. Thase ME, Macfadden W, Weisler RH, et al; BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609.
44. Calabrese JR, Keck PE Jr, Macfadden W. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
45. AstraZeneca. Seroquel (quetiapine fumarate); 2011. Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf. Accessed May 25, 2015.
46. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–1088.
47. Eli L. Symbyax (symbyax olanzapine and fluoxetine hydrochloride); 2013. Available from: http://pi.lilly.com/us/symbyax-pi.pdf. Accessed May 25, 2015.
48. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
49. Sunovion Pharmaceuticals Inc. The US Food and Drug Administration approved Latuda® (lurasidone HCl) for the treatment of adult patients with depressive episodes associated with bipolar I disorder (bipolar depression), both as monotherapy and as an adjunct to lithium or valproate; 2013. Available from: http://www.sunovion.com/news/latuda-press-room.html. Accessed March 21, 2015.
50. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189–210.
51. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder. CNS Drugs. 2012;26(9):733–759.
52. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123(2):153–162.
53. Citrome L, Weiden PJ, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014;19(04):330–339.
54. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147(1):95–102.
55. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–176.
56. Samalin L, Garnier M, Llorca P-M. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239.
57. McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. Expert Opin Pharmacother. 2012;13(11):1653–1659.
58. Kantrowitz JT, Citrome L. Lurasidone for Schizophrenia: What’s different? Expert Review of Neurotherapeutics. 2012;12(3):265–273.
59. Cucchiaro C, Josephine Pikalov A, Ogasa M. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol. 2010;13(suppl 1):217.
60. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2):101–107.
61. Findlay LJ, El-Mallakh P, El-Mallakh RS. Management of bipolar I depression: clinical utility of lurasidone. Ther Clin Risk Manag. 2015;11:75.
62. Preskorn S, Ereshefsky L, Chiu Y-Y, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28(5):495–505.
63. Ehret MJ, Sopko MA Jr., Lemieux T. Focus on lurasidone: a new atypical antipsychotic for the treatment of schizophrenia. Formulary. 2010;45:313–317.
64. Rado J, Janicak PG. Pharmacological and clinical profile of recently approved second-generation antipsychotics. Drugs Aging. 2012;29(10):783–791.
65. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624–1633.
66. Oh GH, Yu J-C, Choi K-S, Joo E-J, Jeong SH. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investig. 2015;12(1):46–54.